Edi Setiawan Tehuteru

Edi Setiawan Tehuteru

Auto-generated profile, based on publicly available information

Edi Setiawan Tehuteru

Hematopoietic Stem Cell Transplantation Unit, Indonesia Tzu Chi Hospital, Jakarta, Indonesia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
GMGhea Mangkuliguna
Ghea Mangkuliguna
ETEdi Setiawan Tehuteru
Edi Setiawan Tehuteru
RJReganedgary Jonlean
Reganedgary Jonlean
NANicholas Adrianto
Nicholas Adrianto
SKStella Kallista
Stella Kallista
Background: Allogeneic stem cell transplantation (allo-SCT) and chimeric antigen receptor (CAR) T-cell therapy offer potential complementary benefits.Purpose: This study aimed to ascertain whether incorporating consolidative allo-SCT after CAR T-cell therapy can augment the therapeutic outcomes of child and young adult patients with relapsed/refractory hematologic malignancy.Methods: A comprehensive literature search of PubMed, ScienceDirect, Cochrane Library, EBSCOHost, ProQuest, and the grey literature repositories was performed for articles published between May 5, 2014, and May 5, 2024. We included studies reporting consolidative allo-SCT following CAR T-cell therapy for treating hematologic malignancies in subjects aged ≤25 years old. The outcomes of interest were complete remission, survival, relapse, and mortality rates. The estimates were pooled using random-effects meta-analysis. The risk of bias was evaluated using the Newcastle-Ottawa Scale, while the certainty of evidence was assessed using GRADE. This study follows the PRISMA 2020 criteria and is registered in the PROSPERO database (CRD42023433417).Results: Twelve cohort studies involving 380 patients, primarily those with B-cell acute lymphoblastic leukemia (B-ALL), were included. The CAR T-cell+SCT group showed a trend toward higher complete remission (odds ratio [OR], 2.74; 95% confidence interval [CI], 0.88–8.54; P= 0.08; I2=57%; evidence, very low); lower mortality (OR, 0.58; 95% CI, 0.27–1.27; P=0.17; I2=0%; evidence, low), and decreased relapse (OR, 0.18; 95% CI, 0.06–0.56; P=0.003; I2=41%; evidence, low) rates than those who did not proceed to SCT. In addition, both overall survival and leukemia-free survival rates showed a favorable trend toward the CAR T-cell+SCT group, respectively (hazard ratio, 0.44; 95% CI, 0.25–0.77; P=0.005; I2=0%; evidence, low; and hazard ratio, 0.29; 95% CI, 0.17–0.49; P<0.00001; I2=0%; evidence, low). Common posttransplant toxicities include mild to moderate acute and chronic graft-versus-host diseases.Conclusion: Although the current level of evidence remains low or very low, allo-SCT following CAR T-cell infusion potentially benefits patient survival. Further clinical studies are required to confirm these findings.

10 August 2025 in Indonesian Journal of Perinatology
Verified
Journal Article
Open access
PDF file
RGRendi Prawira Gunawan
Rendi Prawira Gunawan
AEAnky Tri Rini Kusumaning Edhy
Anky Tri Rini Kusumaning Edhy
ETEdi Setiawan Tehuteru
Edi Setiawan Tehuteru
AWAnak Agung Ngurah Ketut Putra Widnyana
Anak Agung Ngurah Ketut Putra Widnyana
YRYeny Rustina
Yeny Rustina
HTHesti Kristina P Tobing
Hesti Kristina P Tobing
Kangaroo Mother Care (KMC) is a simple and low-cost intervention proven effective in reducing morbidity and mortality among low birth weight (LBW) infants through skin-to-skin contact, exclusive breastfeeding, and post-discharge monitoring. KMC plays an essential role in maintaining the infant’s body temperature, enhancing physiological stability, improving the sucking reflex, accelerating weight gain, and strengthening the emotional bond between mother and baby. In Indonesia, KMC has been integrated into national health policy since 2009 through the “Mother and Baby Friendly Hospital Program,” yet its implementation still faces several challenges, including limited facilities, inadequate health worker training, and insufficient family support. Studies conducted at the hospital and primary care levels have demonstrated positive outcomes in terms of growth, physiological stability, and breastfeeding success among LBW infants who received KMC. The main barriers of KMC implementation in Indonesia are found at the maternal and family level, the healthcare provider and facility level, and also the social-cultural and economic level. Multistage efforts, such as developing legal frameworks, training, teamwork, utilizing the available resources, communication, supervision, documentation, and evaluation, may overcome the barriers and increase the KMC implementation in Indonesia.